The BioNJ Diagnostics and Personalized Medicine Committee was created to advance personalized medicine through diagnostics by identifying and supporting partnerships with industry, academic, government and investors in the State of New Jersey.
The goal of the committee is to define and accelerate new areas of diagnostics, such as in vivo and in vitro tests, biomarkers, imaging, information systems and other innovative technologies.
June 6, 2013: Second Annual Diagnostics & Personalized Medicine Innovation Summit
December 13, 2012: Diagnostics & Personalized Medicine Breakfast Briefing
March 14, 2012: Diagnostics and Personalized Medicine Innovation Summit & Funding Roundtable
May 23-24, 2011: BioPartnering Conference: Bringing Together the Biotech, Diagnostics and Big Pharma Communities.
May 5, 2011: Diagnostics and Personalized Medicine Webinar
September 2010: New Jersey Gets Personalized Breakfast Briefing
July 2010: Kickoff Diagnostic Webinar Featuring G. Steven Burrill
Pascal Yvon, PharmD, MBA, Committee Co-Chair, President, BioSciences Expansion
Yamo Deniz, M.D., Committee Co-Chair, Chief Medical Officer, Global Head, Medical & PV, GE Healthcare Life Sciences
Steve Carchedi, Founding Co-Chair
David Avitabile, President, JFK Communications
G. Steven Burrill, Chief Executive Officer, Burrill & Company
Peter Hoehn, Vice President, Clinical Labs, Janssen Diagnostics
Christopher Moxham, Ph.D., Associate Vice President, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Co.
Roomi Nusrat MD, Aesclepius Sciences
Kathleen Otto, Vice President, Business Development, BioNJ
Panna Sharma, Chief Executive Officer, Cancer Genetics, Inc.
Samir Tari M.D., Founder, PCAsso Diagnostics
Peter Tolias, Ph.D., Director, Center for Healthcare Innovation and Professor, Department of Chemistry, Chemical Biology and Biomedical Engineering, Stevens Institute of Technology